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How did the study come about?
Thanks to continuous improvements in therapy, 5-year survival of childhood cancer in developed countries now exceeds 80%, 1, 2 leading to a growing population of long-term survivors. As the cancer and treatment can cause adverse effects long after the illness has been cured, assessment of long-term quality of life (QOL), somatic, psychological and social outcomes become increasingly important. Although cancer in children is rare, the population impact of late toxicities on disability-adjusted life years is considerable because of the young age at diagnosis.
Up to now, many single-centre studies or clinical trials have been published, but only few large representative long-term follow-up studies exist, including the Childhood Cancer Survivor Studies in the USA (CCSS), 3 Canada 4 and Great Britain (BCCSS). 5 These studies found increased risks of second malignant neoplasms (SMNs), 6 mortality 7, 8 and chronic medical problems such as endocrine dysfunctions, cardiovascular problems, stroke or infertility. [9] [10] [11] Psychosocial problems such as depression, anxiety and post-traumatic symptoms have also been reported. 12, 13 Life-long medical follow-up is thus recommended for high-risk patients. 14, 15 For these reasons, we created a national cohort study of all survivors of childhood and adolescent cancer in Switzerland, the Swiss Childhood Cancer Survivor Study (SCCSS).
What does it cover?
The SCCSS is a nationwide population-based cohort study of all children diagnosed with cancer in Switzerland since 1976, which aims to study longterm consequences of childhood cancer, including mortality, SMNs, QOL, late somatic, psychological and social effects, health behaviours and health care.
In particular, the SCCSS aims to:
(i) determine the incidence of late effects of cancer and treatments, including overall and causespecific mortality, SMNs, somatic toxicities (endocrine disorders, infertility and pregnancy complications, cardiovascular, pulmonary and orthopaedic problems), health-related QOL and psychosocial outcomes including psychological distress, educational and professional attainment; (ii) study associations between adverse outcomes and prospectively collected risk factors, including tumour (exact diagnosis, histology, cytogenetics, tumour stage and clinical features at diagnosis), treatment modalities (chemotherapy, radiotherapy, surgery), participation in clinical trials, age, sex, nationality, geographic region and socio-economic position of parents; (iii) describe the current health-care use and medical follow-up in survivors, including type of health care, frequency of visits and uptake of recommended screening procedures and (iv) describe health-related behaviours and their determinants in survivors compared with the general population.
The SCCR is the population-based cancer registry for all Swiss residents diagnosed <21 years of age with leukaemias, lymphomas, central nervous system (CNS) tumours, malignant solid tumours or Langerhans cell histiocytosis. [16] [17] [18] [19] [20] It was founded in 1976. Case ascertainment is excellent for children aged 0-15 years at diagnosis who are usually treated in one of the nine specialized paediatric cancer centres (Figure 1 ). Regular comparison of the SCCR with data sets from cantonal cancer registries, Swiss hospital statistics, major pathology laboratories and mortality statistics allows the integration of patients who had not been treated in paediatric cancer centres.
Adolescents aged 16-20 years at diagnosis are also registered in the SCCR. However, coverage of this age group is still unsatisfactory, because only a minority of adolescents in Switzerland are treated in paediatric cancer centres. Instead, care is shared between a large and heterogeneous group of specialists and hospitals, such that not all cases are reported. 21 The SCCR aims for a complete coverage of adolescents by the year 2015.
By 31 December 2010, the SCCR included information on 5553 Swiss residents with cancer diagnosed at the age of 0-15 years (Table 1) . Of these, 2435 (44%) had been diagnosed at the age of 0-4 years, 1423 (26%) at age 5-9 years and 1695 (31%) at age 10-15 years; 3143 (57%) were males and 2410 (43%) females. The most common diagnosis was leukaemias (34%), followed by CNS tumours (18%), lymphomas (14%), neuroblastoma (7%), soft tissue sarcomas (6%) renal tumours (5%) and bone tumours (5%). In total, 1395 patients (25%) had died.
The SCCSS (Figure 2 ) is the long-term cohort study of all patients registered in the SCCR who survived 55 years. For the questionnaire survey 2007-11, only children diagnosed from 1976 to 2003, in the age group of 0-15 years, were included (N ¼ 2738). From 2011, the study will be extended to include adolescents diagnosed at the age of 16-20 years (n 1200), children not treated in a paediatric cancer centre (n 500), children diagnosed between 2003 and 2005 (n ¼ 463) and children who had been registered in the SCCR after December 2003 although diagnosed earlier (n ¼ 160, Figure 2 ).
What has been measured?
The data collected for the SCCR and the SCCSS come from three sources:
(i) clinical data from medical records; (ii) routine data on current address, vital status, SMNs and causes of death; and (iii) questionnaire surveys and examinations.
These are briefly described below, with details given in Tables 2 and 3 . Clinical data from medical records Information at the time of diagnosis Children are usually registered in the SCCR within 3 months of diagnosis with standardized forms completed by local data managers of the paediatric cancer centres. In the SCCR, these forms are entered in the database after verification of missing or incorrect data. For cases not treated in paediatric cancer centres but identified via other sources [cantonal cancer registries, pathology laboratories, mortality statistics for death certificate only (DCO) cases], we migrate information into the SCCR in regular intervals. If not already available, an SCCR data manager extracts relevant information directly from hospital records. 
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Information includes baseline demographic data and detailed medical information on the tumour, therapy and response to therapy. 16, 17 Diagnoses are classified according to the International Statistical Classification of Diseases and Related Health Problems, 10th Revision (ICD-10), the International Classification of Diseases for Oncology, Third Edition (ICD-O3) and the International Classification of Childhood Cancer, third edition (ICCC-3).
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Clinical follow-up data As long as children are treated and followed up in paediatric cancer centres (usually 5-10 years from the time of diagnosis), follow-up information on remissions and relapses, changes in treatments and clinical study participation is extracted annually from patient records by local data managers. Similarly, late effects, SMNs or deaths occurring during this period are registered.
Routine data and linkages First, current address, vital status and date of death have been updated in a standardized way in 2005-10 for the whole cohort by contacting community registration offices.
Causes of death and death records are identified periodically from the Swiss mortality statistics in the Swiss Federal Statistical Office. The SCCR data are linked with the anonymous mortality statistics via Information on peri-natal data, environmental exposures and socio-economic situation for cohort participants and matched controls can be obtained via data linkage with the Swiss National Cohort, 23 a large national cohort study combining data from the Swiss censuses, mortality statistics, migration records and birth records. 18 Secondly, malignant neoplasms are being assessed (in 2010-11) via linkage with Swiss cantonal cancer registries, organized in the National Institute for Cancer Epidemiology and Registration (NICER; www.nicer.org). For linkage, we use a privacy-protecting technique using Bloom filters. 24 From 2012, this linkage will be repeated annually to detect new cases.
Surveys and examinations
A first long-term follow-up survey was performed in 1994-96. 15, [25] [26] [27] A total of 478 5-year survivors attended follow-up at their former hospital for a standardized medical history, a comprehensive clinical examination and additional investigations focusing on somatic, psychosocial and socio-economic outcomes [e.g. intelligence using the Wechsler Intelligence Scale for Children/Wechsler Adult Intelligence Scale Figure S1 ). All participants with a known address received a study information letter from their former treating hospital. They were asked to indicate if their address had changed, if they required the questionnaire in a language other than Table 3 Clinical data, routine data and survey data collected in the SCCSS: available data (n) (status December 2010, measurements described in detail in Table 2 the information letter (German, French or Italian) or if they did not want to participate. After 2 weeks, they received the questionnaire with a pre-paid return envelope. Non-responders were sent another questionnaire 4-6 weeks later and in case of not answering, were contacted by phone. If they felt that the questionnaire was too long, they were offered a short version with key questions. Self-reported somatic health problems are validated by comparison with medical records from general practitioners or hospitals. This will be done in 2011 for cardiac disease and SMNs, and will be extended to other outcomes in subsequent years. Informed consent for this validation has been collected in the questionnaire.
The SCCSS questionnaire
The questionnaire was created based on those used in the US, Canadian and UK childhood cancer survivor studies [3] [4] [5] to enable international comparison of health outcomes. It contains the following main domains: QOL, somatic health, current medication, health service utilization, psychological distress, fertility, health behaviour and socio-economic information.
In addition to the questions from the US, UK and Canadian questionnaires, we included the Brief Symptom Inventory (BSI) assessing psychological distress, 29, 30 and added more questions on health behaviours and socio-economic information. Unique for the SCCSS is the inclusion of not only the cancer survivors who have reached adulthood, but also younger 5-year survivors.
To account for age-dependent differences, we created three distinct questionnaires: for adult survivors (aged 520 years), adolescents (aged 16-19 years) and children (aged 5-15 years). Details of the content of the questionnaire are described in Table 4 . The questionnaires in German, French and Italian are available on our homepage (http://www.childhoodcancerregistry .ch/sccss).
Control data sets for the questionnaire 2007-11
For comparing answers of study participants with healthy controls, we took two different approaches:
(i) sibling questionnaire-in 2009-11, the same questionnaires (excluding questions on past disease and treatments) are being sent to siblings of the study participants; and (ii) population health surveys-in addition to questions derived from other childhood cancer survivor studies, [3] [4] [5] we included questions on QOL, health behaviours and socio-economic outcomes, which were used during the same years in general population health surveys in Switzerland. This allows a straightforward comparison of specific outcomes between survivors and the Swiss general population (Table 4) . 29, [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] Study participation and attrition In the 1994-96 survey, the SCCR contained information on 914 5-year survivors. All patients (n ¼ 750) for whom a valid address was found were invited to attend follow-up at their former hospital, and 478 (64%) participated (Table 3) . 26 In the 2007-11 survey, 2738 eligible survivors were mailed a questionnaire (1647 adults aged 20-49 years at the survey, 470 adolescents aged 16-19 years and 621 children aged 5-15 years; Figure 2) . For 134 survivors, we had no valid address, 119 refused and 367 did not answer. Current response rates (31 December 2010) were: 1193 adults (78% of contacted) and 312 adolescents (69% of contacted) ( Tables 3 and  5 ). Mailing of questionnaires to families of children aged 5-15 years and siblings takes place from October 2010 to June 2011. Provisional response rate for the sibling mailing is 451/749 (60%). Respondents to the questionnaire were more likely to be female, German speaking and aged 25-35 years compared with non-respondents (Table 5) .
What has been found? Key findings and publications

Somatic outcomes
The first survey (1992-94) collected detailed data on somatic and cognitive outcomes. 15, [25] [26] [27] Moderate to severe late effects were found in 211/621 (34%) survivors. 26 A subgroup of 140 acute lymphoblastic leukaemia (ALL) survivors was studied in detail. 25, 27 Of those, 21/140 (15%) had moderate to severe late effects, 8 needed special schooling and 14 had problematic psychosocial adjustments. Most survivors suffered from endocrinological abnormalities (20/140, 14%). Problems of the cardiovascular system, lung, liver and digestion were rare (overall 9/140, 6%). 25 These findings resulted in the development of Swiss recommendations for long-term follow-up of childhood cancer survivors. 15 In male survivors of acute lymphoblastic leukaemia, we assessed gonadal function and sperm quality. While sex hormone levels were normal, sperm concentration and sperm counts were decreased compared with WHO criteria and healthy controls, suggesting that treatment with moderately dosed chemotherapeutic agents, even without added radiotherapy, might have long-term gonadotoxic effects. 42 Prevalence of bronchial asthma, assessed in the 2007-11 survey in young adult survivors, was similar to data published from general population samples in Switzerland. 43 Psychological and socio-economic outcomes In the 2007-11 survey, we assessed psychological distress in young adult childhood cancer survivors and found that average distress scores were similar to normal populations. However, the proportion reporting THE SWISS CHILDHOOD CANCER SURVIVOR STUDY high distress was disproportionally large, suggesting that a significant number of survivors might benefit from psychological counselling. 30 A considerable proportion of childhood cancer patients had transient problems with schooling, but final educational attainment in adulthood was comparable with the general population. Only CNS tumour survivors and survivors with a relapse had poorer outcomes. 44 Health behaviours A healthy lifestyle is important to prevent chronic diseases in the general population and even more relevant for childhood cancer survivors. In 835 young adult survivors and 1670 matched controls, latent class analysis identified four distinct behaviour patterns: 'risk-avoiding'-with a generally healthy behaviour; 'moderate drinking'-with higher levels of physical activity 45 but moderate alcohol consumption; 'risktaking'-engaging in several risk behaviours (alcohol, tobacco and marijuana consumption); and 'smoking'-including smoking but not drinking. A considerable proportion of survivors and controls (14 vs 12%) engaged in multiple risk behaviours. Survivors were more likely to be in the 'moderate drinking' and less likely to be in the 'smoking' group, indicating a greater awareness of health compromising effects of tobacco than alcohol. Compared with the general population, 46 survivors engaged in binge drinking later in life compared with healthy peers.
Medical care in long-term survivors of childhood cancer Well-organized medical follow-up is important to detect and treat late effects in survivors. However, we found that only a minority of adult survivors of childhood cancer in Switzerland have regular followup, and few received written documentation on their diagnosis, therapy and advice for future medical check-ups.
14 An important barrier for not attending follow-up was the belief that follow-up is not necessary. 47 On-going and planned studies New 5-year survivors are integrated continuously into the SCCSS. This makes numbers of the cohort and response rates fluctuate with time. We plan to send the participants a follow-up questionnaire every 5 years. The next is planned for 2015.
A study funded by the European Union FP7 (PanCareSurFup; running 2011-15) pools data from the SCCSS with data from other European countries, to construct a European cohort of childhood cancer survivors. It aims to describe late mortality, SMNs and cardiac late effects and determine risk factors. Radiation doses and chemotherapeutic agents received will be studied in detail. An on-going research programme (2009-12) on follow-up care funded by the Swiss National Science Foundation (SNF) studies different models of followup for childhood cancer survivors in Switzerland and Europe. In addition, all survivors in Switzerland who replied in 2007-11 will receive a questionnaire about their needs and desires for follow-up care after childhood cancer and how they would like to see it organized. Oncologists and general practitioners receive a similar questionnaire. [48] [49] [50] Two projects nested in the SCCSS (from 2011 to 2014; funded by the SNF and the Swiss Cancer League) focus on transition from paediatric to adult follow-up care in Switzerland.
Results from all these studies will provide the basis to develop a standardized model of follow-up for survivors of childhood and adolescent cancer in Switzerland and Europe.
What are the main strengths and weaknesses?
Strengths of the SCCSS are:
(i) the close link with the national childhood cancer registry and paediatric oncology clinics allows easy access to routine data and clinical information from medical records. Additionally, research findings can promptly be translated into daily practice; (ii) the high response rate makes results representative for the majority of childhood cancer survivors in Switzerland; (iii) the SCCSS can easily be extended to assess later outcomes in current survivors and to include new survivors treated with more recent therapies; and (iv) results of the SCCSS can be compared with results for representative population-based studies performed simultaneously in Switzerland, with results from siblings and with other childhood cancer survivor studies.
Limitations of the study are:
(i) the number of survivors of certain rare cancers and specific therapies in Switzerland is small, limiting the ability to study rare outcomes. This limitation can be overcome by international pooling of data, as in the incipient EU FP7 survey; and (ii) although the first late effects study included a standardized medical examination and measurements, outcomes assessed in 2007-11 were based on self-reports from a questionnaire. However, we will validate important outcomes with medical records.
Can I get hold of the data? Where can I find out more?
The SCCR and the SCCSS are collaborative projects between the Swiss Paediatric Oncology Group (SPOG) and the Institute of Social and Preventive Medicine, University of Bern, Switzerland. Our homepage displays detailed information on methods, results and publications (www.childhoodcancerregistry .ch). Researchers interested in collaborative work can contact the principal investigators (Claudia Kuehni, kuehni@ispm.unibe.ch and Nicolas von der Weid, Nicolas.von-der-Weid@chuv.ch) to discuss planned projects or analyses of existing data. The final decision will be made upon presentation of the project to the Scientific Council of the SPOG. 
